Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

CircRNA expression-profiling to predict prognosis in locoregionally advanced nasopharyngeal carcinoma

ABSTRACT: CircRNA expression-profiling to predict prognosis in locoregionally advanced nasopharyngeal carcinoma

PROVIDER: PRJNA786569 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

CircRNA expression-profiling to predict prognosis in locoregionally advanced nasopharyngeal carcinoma

Project description:CircRNAs serve as prognostic biomarkers in various types of cancer. We aimed to identify a circRNA signature for individual relapse risk assessment in patients with locoregionally advanced nasopharyngeal carcinoma (LA-NPC).

2023-12-21 | GSE190271 | GEO

Gene expression-profiling to predict induction chemotherapy efficacy in locoregionally advanced nasopharyngeal carcinoma

Project description:Gene expression signature can be used to predict treatment efficacy in various types of tumour. We aim to identify a gene expression signature to predict efficacy of induction chemotherapy (IC) in patients with locoregionally advanced nasopharyngeal carcinoma (LA-NPC).

2021-04-14 | GSE132112 | GEO

LncRNA expression-profiling to predict distant metastasis in locoregionally advanced nasopharyngeal carcinoma

Project description:LncRNAs can be used as prognostic biomarkers in various types of cancer. We aimed to identify a lncRNA expression pattern for individual distant metastatic risk assessment in patients with locoregionally advanced nasopharyngeal carcinoma (LA-NPC).

2022-04-10 | GSE180272 | GEO

Gene expression-profiling to predict distant metastasis in locoregionally advanced nasopharyngeal carcinoma

Project description:Gene expression patterns can be used as prognostic biomarkers in various types of cancer. We aimed to identify a gene expression pattern for individual distant metastatic risk assessment in patients with locoregionally advanced nasopharyngeal carcinoma (LA-NPC).

2019-05-02 | GSE103611 | GEO

Plasma protein-profiling to predict distant metastasis in locoregionally advanced nasopharyngeal carcinoma (LA-NPC)

Project description:Plasma protein expression patterns can be used as prognostic biomarkers in various types of cancer. We aimed to identify a protein-based signature for distant metastatic risk assessment in patients with locoregionally advanced nasopharyngeal carcinoma (LA-NPC).

2020-09-02 | GSE149587 | GEO

LncRNA expression-profiling to predict distant metastasis in locoregionally advanced nasopharyngeal carcinoma

Project description:LncRNA expression-profiling to predict distant metastasis in locoregionally advanced nasopharyngeal carcinoma

| PRJNA747297 | ENA

Gene expression-profiling to predict induction chemotherapy efficacy in locoregionally advanced nasopharyngeal carcinoma

Project description:Gene expression-profiling to predict induction chemotherapy efficacy in locoregionally advanced nasopharyngeal carcinoma

| PRJNA545965 | ENA

Plasma protein-profiling to predict distant metastasis in locoregionally advanced nasopharyngeal carcinoma (LA-NPC)

Project description:Plasma protein-profiling to predict distant metastasis in locoregionally advanced nasopharyngeal carcinoma (LA-NPC)

| PRJNA629317 | ENA

Induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma.

Project description:The value of adding induction chemotherapy (IC) to concurrent chemoradiotherapy (CCRT) for the treatment of locoregionally advanced nasopharyngeal carcinoma (NPC) remains unclear. In our recent article entitled "Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial" published in the Lancet Oncology, we reported the results of a phase III, multicenter, randomized controlled trial comparing cisplatin, 5-fluorouracil, and docetaxel (TPF) IC plus CCRT versus CCRT alone in patients with T3-4N1/TxN2-3M0 NPC (ClinicalTrials.gov registration number NCT01245959). The IC-plus-CCRT group showed significantly higher 3-year failure-free survival, overall survival, and distant failure-free survival rates than the CCRT-alone group, with an acceptable toxicity profile. Our study suggests that adding TPF IC to CCRT could increase survival rates and reduce distant failure in patients with locoregionally advanced NPC. However, long-term follow-up is required to assess the eventual efficacy and toxicity of this strategy, and a more accurate method to determine prognosis is needed to enable better tailoring of treatment strategy for individual patients.

| S-EPMC5111216 | biostudies-literature

Oncogenic Pathway Combinations Predict Clinical Prognosis in Gastric Cancer

Project description:Oncogenic Pathway Combinations Predict Clinical Prognosis in Gastric Cancer

| PRJNA115897 | ENA